Thu, Jul 24, 2014, 10:18 AM EDT - U.S. Markets close in 5 hrs 42 mins

Recent

% | $
Click the to save as a favorite.

Ironwood Pharmaceuticals, Inc. Message Board

  • jrus2010 jrus2010 Jan 31, 2013 7:05 AM Flag

    Quality of the data will ensure Linzess predominance

    As details of Synergy's clinical trials emerge, I expect investors to realize important differences in trial design and quality of the data that will make it clear that Ironwood's drug will be the only agent of its class on the market for the foreseeable future. Channel checks indicate rapid uptake and increasing traction for Linzess in January which will translate to better than expected revenue growth.

    Sentiment: Strong Buy

 
IRWD
15.10+0.05(+0.33%)10:18 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.